Brookline analyst Tyler Bussian initiated coverage of CervoMed with a Buy rating and $63 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed announces addition to Russell 2000, Russell 3000 Indexes
- CervoMed announces completion of enrollment in Phase 2b RewinD-LB trial
- CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy Bodies
- CervoMed initiated with a Buy at JonesResearch
- CervoMed appoints Elder as Chief Financial Officer